Medico Remedies (MEDICO)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 48.59% demonstrates strong demand and momentum in the pharmaceutical segment.
• ROE of 20.90% and ROCE of 21.31% show efficient capital deployment.
• Low debt/equity of 0.19 provides financial cushion.
• Piotroski F-Score of 7/9 indicates healthy fundamentals across profitability, leverage, and efficiency.
• Promoter holding of 61.38% aligns management interests with minority shareholders.

Concerns

• P/E of 31.86 and P/B of 6.49 offer little safety margin versus book value of ₹6.50.
• Profit growth of 9.54% is far below sales growth of 48.59%, indicating margin compression.
• Latest quarter net margin is small (₹3 Cr profit on ₹59 Cr sales), so earnings quality needs monitoring.
• No dividend means investors rely solely on capital gains.

AI Analysis

At ₹42.19, I cannot call Medico Remedies a Graham bargain. The market cap of ₹370 Cr is supported by a P/E of 31.86 and a P/B of 6.49, while book value is just ₹6.50. In Benjamin Graham's arithmetic, that leaves little margin of safety. What does the business show for this premium? Sales grew 48.59%, but profit grew only 9.54%. The latest quarter's ₹59 Cr of revenue produced just ₹3 Cr of net profit—a thin margin that tells me revenue is expanding without comparable earnings power. This is often the signature of a price-taker in a competitive pharmaceutical market, not a franchise with pricing power. The return ratios, ROE of 20.90% and ROCE of 21.31%, are respectable, and a debt/equity ratio of 0.19 keeps financial risk modest. A Piotroski score of 7/9 also suggests the balance sheet is not deteriorating. Promoter holding of 61.38% is reassuring; owners have skin in the game. But attractive operations do not justify any price. I see no dividend to compensate while waiting, so every rupee of expected return must come from future price appreciation. With profit growth in single digits, paying 31.86 times earnings means the market is already expecting a surge in margins or a long runway. I would rather wait for evidence that the profit line can match the top line. The 52-week range of ₹30.22–₹56.99 shows the stock has been volatile; a better entry would provide some cushion. In short, this is a decent small pharma story with good capital allocation discipline, but at today's price the optimism is already in the price. I need a margin of safety before I commit.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer